

30th May, 2018

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub: Compliances under Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for half year ended 31st March, 2018

In continuation to our letter dated 30th May, 2018, submitting the Financial Results of the Company for the quarter and year ended on 31st March, 2018, please find below the NCD payment Schedule and credit rating as required under Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) with respect to Company’s privately placed secured/unsecured non convertible debentures:

Sr No	ISIN Number	Previous due date		Next Redemption		Next Interest Payment		Credit Rating
		Principal	Interest	Principal Amount	Due Date	Interest Amount	Due Date	
1	INE685A07025	-	23-Jun-17	84,00,00,000	22-Jun-18	7,70,68,273.80	22-Jun-18	ICRA AA Stable
2	INE685A07033	-	23-Jun-17	83,00,00,000	24-Jun-19	7,61,50,794.35	22-Jun-18	ICRA AA Stable
3	INE685A07041	-	23-Jun-17	83,00,00,000	24-Jun-20	7,61,50,794.35	22-Jun-18	ICRA AA Stable
4	INE685A07058	26-Mar-18	26-Mar-18	91,20,00,000	25-Mar-19	13,65,20,942.47	25-Mar-19	ICRA AA Stable

 1

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

5	INE685A070 66	-	13- Dec-17	100,00,00, 000	13- Dec-18	39,75,00,000	13- Dec- 18	ICRA AA Stabl e
6	INE685A070 74	-	29- Dec-17	1,66,65,00, 000	28- Dec-18	38,89,30,000	28- Dec- 18	ICRA AA Stabl e
7	INE685A080 15	-	-	500,00,00, 000	29- Nov-18	34,52,05,479. 45	29- Nov- 18	IND A1+
8	INE685A070 82	-	-	142,86,00, 000	13- Dec-19	As per coupon reset	14- Dec- 18	ICRA AA Stabl e

Interest/Principal has been paid on or before the due dates.


Further, please find enclosed herewith the certificate received from IDBI Trusteeship Services Limited, Debenture Trustee as per Regulation 52(5) of Listing Regulations stating that they have taken note of the relevant information pertaining to the half year ended on 31st March, 2018.

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

No. 2135 /ITSL/OPR/2018-19
May 30, 2018

To,
Torrent Pharmaceuticals Limited,
Torrent House,
Off Ashram Road,
Ahmedabad 380009,

Dear Sir,

Sub: Letter of Debenture Trustee pursuant to Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2018

This has reference to the Unsecured/Secured, Non-Convertible Debentures issued by **Torrent Pharmaceuticals Limited** ("Issuer") wherein IDBI Trusteeship Services Limited is acting as the Debenture Trustee and listed on the Bombay Stock Exchange (BSE) and/or National Stock Exchange (NSE) ("**Listed Debt Securities**").

Pursuant to Regulation 52(4) read with Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) 2015, the Issuer is required to submit the documents required there along with its half yearly/annual financial results to the Stock Exchange, with a letter of the Debenture Trustee (IDBI Trusteeship Services Limited) that the Debenture Trustee has noted the contents furnished by the Issuer as per Regulation 52(4).

In pursuance thereof we hereby confirm that we have received the aforesaid information through your letter dated May 30, 2018 and we have noted the contents provided therein.

Thanking you,

Yours faithfully
For **IDBI Trusteeship Services Limited**


Authorised Signatory

